Welcome to our dedicated page for Syneos Health news (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health stock.
Syneos Health, Inc. (Nasdaq: SYNH) is a prominent player in the biopharmaceutical solutions industry, offering comprehensive end-to-end clinical and commercial services. With a mission to shorten the distance from lab to life, the company is dedicated to accelerating the success of its clients in the biopharmaceutical sector.
Formed from the merger of INC Research and inVentiv Health, Syneos Health stands out as the only fully integrated biopharmaceutical solutions organization. The company leverages its extensive expertise and data insights to navigate the complexities of today's marketplace, providing smarter and faster solutions to its clients. Its services range from clinical trials to commercialization, ensuring that therapies reach patients efficiently.
Headquartered in Morrisville, N.C., Syneos Health operates in more than 110 countries, employing a talented team of professionals who deeply understand patient and physician behaviors as well as market dynamics. The company is committed to fostering a diverse, equitable, and inclusive culture, focusing on the well-being of its colleagues, customers, patients, communities, and the environment.
One of Syneos Health's recent significant achievements includes an agreement to go private through an acquisition by a consortium of private investment firms, which includes Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital. This transaction, approved by the company's stockholders, is expected to bolster Syneos Health's growth priorities and enhance its ability to deliver integrated solutions to its clients.
Among its current projects, Syneos Health has been enhancing its patient recruitment capabilities through a collaboration with Oracle Cerner LHN to address unmet needs in clinical trial enrollment and diversity. Furthermore, the company continues to invest in technology and data solutions to optimize clinical development and performance for its customers.
Financially, Syneos Health operates on solid footing, with ongoing support from its new private investors poised to further accelerate its transformation and fuel investments in technology. The company's commitment to innovation and customer success positions it as a leading force in the biopharmaceutical industry.
To stay updated on Syneos Health's latest developments, including their quarterly reports and strategic initiatives, visit syneoshealth.com and subscribe to their podcast.
Phil Inc. has announced an exclusive partnership with Syneos Health (NASDAQ:SYNH), aiming to enhance patient prescription access through a comprehensive commercialization solution. Phil will provide HUB-related services exclusively for Syneos, which will in turn offer Phil preferred outsourced services. This collaboration focuses on streamlining the prescription process, ensuring patients can quickly and affordably start and maintain their therapies. Both companies emphasize their commitment to improving patient outcomes and the overall prescription management experience.
Syneos Health (Nasdaq:SYNH) will announce its Q3 2022 financial results on November 4, 2022, before an earnings call at 8:00 a.m. ET. Participants can join the call by registering in advance through their website. A replay of the webcast will be accessible after 1:00 p.m. on the same day. Syneos Health, a fully integrated biopharmaceutical solutions organization, employs over 29,000 professionals across 110 countries, focusing on improving the delivery of therapies to patients through advanced integration of clinical, medical, and commercial capabilities.
Syneos Health (Nasdaq: SYNH) announced the appointment of William E. Klitgaard to its Board of Directors, marking his return after resigning in May 2022. Klitgaard brings extensive financial experience and familiarity with the company, enhancing Board strength. The company also expressed gratitude to Todd M. Abbrecht, who is stepping down. Klitgaard will serve as a Class II director and on the Audit Committee, maintaining a Board composition of 10 directors, 9 of whom are independent. This leadership change is expected to bolster oversight of Syneos Health's strategic direction.
Syneos Health (Nasdaq:SYNH) has announced an expanded partnership with Datavant to enhance clinical trial tokenization and analytics capabilities. This collaboration aims to accelerate the development and commercialization of new therapies by utilizing Datavant Switchboard and its data ecosystem. The integration will improve the efficiency of clinical trials, enhance Medical Affairs, Market Access, and Commercial Analytics, and optimize product launch trajectories. Datavant's Privacy Hub will facilitate compliant data sharing, reinforcing Syneos Health's position in the biopharmaceutical solutions sector.
Syneos Health (Nasdaq:SYNH) will be represented by CEO Michelle Keefe and CFO Jason Meggs at the 2022 Baird Global Healthcare Conference on September 13, 2022, at 2:00 p.m. ET. A webcast of their presentation, including materials and a replay, will be available on the Company’s Investor Relations website.
physIQ has announced a strategic collaboration with InCarda Therapeutics to advance InRhythm™, an inhaled treatment for atrial fibrillation (AF). This Phase III RESTORE-1 study employs innovative trial design using wearable sensors and FDA-cleared biomarkers to screen and enroll 400 patients efficiently across Europe and North America. The study aims to demonstrate faster restoration of normal sinus rhythm through real-time data acquisition. The collaboration is expected to enhance patient enrollment and treatment efficacy for the significant population affected by AF.
Syneos Health reported Q2 2022 revenue of $1,360.7 million, reflecting a 6.1% increase year-over-year, driven by Clinical and Commercial Solutions growth. Clinical Solutions revenue rose 3.3%, while Commercial Solutions increased 15.7%. However, net new business awards fell 34.2% year-over-year, with a book-to-bill ratio of 0.92x. GAAP net income surged 85.5% to $77.7 million, achieving $0.75 EPS. The company revised its FY 2022 guidance, anticipating lower reimbursable expenses and foreign exchange impacts.
Syneos Health (Nasdaq:SYNH) will release its Q2 2022 financial results on August 2, 2022, before its earnings call at 9:00 a.m. ET. Investors can access the call via the company's Investor Relations webpage. A replay will be available post-call. As a fully integrated biopharmaceutical solutions organization, Syneos Health focuses on enhancing customer success through a blend of clinical development, medical affairs, and commercial capabilities. The company operates in over 110 countries, leveraging advanced technologies and insights to expedite therapy delivery.
Syneos Health (Nasdaq:SYNH) announced its participation in two key investor conferences. CEO Michelle Keefe and CFO Jason Meggs will present at the 42nd Annual William Blair Growth Stock Conference in Chicago on June 6, 2022, at 3:20 p.m. CT and the Jefferies Healthcare Conference in New York on June 8, 2022, at 3:30 p.m. ET. Both events will feature live webcasts accessible through the Company’s Investor Relations website. Syneos Health is a fully integrated biopharmaceutical solutions organization dedicated to advancing customer success.
FAQ
What is the market cap of Syneos Health (SYNH)?
What is Syneos Health, Inc.?
What recent achievement did Syneos Health announce?
What services does Syneos Health offer?
What is the significance of Syneos Health's collaboration with Oracle Cerner LHN?
How many countries does Syneos Health operate in?
What is Syneos Health's commitment to diversity and inclusion?
What is Syneos Health's financial condition?
Where can I find more information about Syneos Health's latest developments?
What is the main goal of Syneos Health?
Who are the private investment firms involved in the acquisition of Syneos Health?
